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DOI 10.1186/s12916-014-0253-8RESEARCH ARTICLE Open AccessEffects on mortality of a nutritional intervention
for malnourished HIV-infected adults referred for
antiretroviral therapy: a randomised controlled trial
NUSTART (Nutritional Support for Africans Starting Antiretroviral Therapy) Study Team, Suzanne Filteau1*,
George PrayGod2, Lackson Kasonka3, Susannah Woodd1, Andrea M Rehman1, Molly Chisenga3, Joshua Siame3,
John R Koethe4, John Changalucha2, Denna Michael2, Jeremiah Kidola2, Daniela Manno1, Natasha Larke1,
Daniel Yilma5, Douglas C Heimburger4, Henrik Friis6 and Paul Kelly3,7Abstract
Background: Malnourished HIV-infected African adults are at high risk of early mortality after starting antiretroviral
therapy (ART). We hypothesized that short-course, high-dose vitamin and mineral supplementation in lipid nutritional
supplements would decrease mortality.
Methods: The study was an individually-randomised phase III trial conducted in ART clinics in Mwanza, Tanzania, and
Lusaka, Zambia. Participants were 1,815 ART-naïve non-pregnant adults with body mass index (BMI) <18.5 kg/m2 who
were referred for ART based on CD4 count <350 cells/μL or WHO stage 3 or 4 disease. The intervention was a
lipid-based nutritional supplement either without (LNS) or with additional vitamins and minerals (LNS-VM), beginning
prior to ART initiation; supplement amounts were 30 g/day (150 kcal) from recruitment until 2 weeks after starting
ART and 250 g/day (1,400 kcal) from weeks 2 to 6 after starting ART. The primary outcome was mortality between
recruitment and 12 weeks of ART. Secondary outcomes were serious adverse events (SAEs) and abnormal electrolytes
throughout, and BMI and CD4 count at 12 weeks ART.
Results: Follow-up for the primary outcome was 91%. Median adherence was 66%. There were 181 deaths in the
LNS group (83.7/100 person-years) and 184 (82.6/100 person-years) in the LNS-VM group (rate ratio (RR), 0.99; 95% CI,
0.80–1.21; P = 0.89). The intervention did not affect SAEs or BMI, but decreased the incidence of low serum phosphate
(RR, 0.73; 95% CI, 0.55–0.97; P = 0.03) and increased the incidence of high serum potassium (RR, 1.60; 95% CI, 1.19–2.15;
P = 0.002) and phosphate (RR, 1.23; 95% CI, 1.10–1.37; P <0.001). Mean CD4 count at 12 weeks post-ART was 25 cells/μL
(95% CI, 4–46) higher in the LNS-VM compared to the LNS arm (P = 0.02).
Conclusions: High-dose vitamin and mineral supplementation in LNS, compared to LNS alone, did not decrease
mortality or clinical SAEs in malnourished African adults initiating ART, but improved CD4 count. The higher frequency
of elevated serum potassium and phosphate levels suggests high-level electrolyte supplementation for all patients is
inadvisable but the addition of micronutrient supplements to ART may provide clinical benefits in these patients.
Trial registration: PACTR201106000300631, registered on 1st June 2011.
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The last decade has seen great advances in expanding
access to antiretroviral therapy (ART) for HIV-infected
Africans. However, high mortality in the first few months
of ART remains a major concern [1,2]. Consistent risk fac-
tors for early mortality include low CD4 count, advanced
WHO disease stage, the presence of opportunistic infec-
tions such as tuberculosis (TB), and malnutrition, usually
indicated by low body mass index (BMI) [1,3,4].
Food insecurity, though widespread in much of Africa,
is unlikely to be the main cause of low BMI among HIV-
infected Africans. Asymptomatic HIV infection increases
basal energy requirements by approximately 10%, and
up to 30% among those with opportunistic infections,
while intestinal malabsorption, also frequently observed
in HIV, reduces nutrient uptake from food [5]. Anorexia,
common among HIV patients, is probably the most
important contributor to loss of cell mass and prevents
weight regain until appetite returns [6]. A belief that
managing infections through ART and other anti-
microbial treatment will be sufficient to reverse the nutri-
tional deficits may have contributed to the neglect of
nutrition in HIV treatment policies. This view ignores a
large literature on management of malnutrition among a
different group: young children [7].
Even if malnutrition is secondary to infection, it re-
quires careful nutritional intervention. Although inten-
sive feeding of malnourished children to permit regain
of weight might seem the obvious intervention, there
is evidence that this is associated with increased mor-
tality [7]. This is because severe malnutrition is asso-
ciated with metabolic abnormalities, the hallmark of
which is hypophosphataemia, which is often accom-
panied by disordered sodium/potassium balance and
oedema. Recent evidence suggests that low plasma
phosphate is also present among malnourished Africans
starting ART and is an independent risk factor for early
mortality [8,9].
Malnutrition is also associated with altered iron me-
tabolism and provision of iron before metabolic iron-
control mechanisms are restored may result in increased
infections or oxidative stress [10]. Current practice is to
treat severely malnourished children in two stages: first
a stabilisation phase during which infections are cleared
and metabolic abnormalities are reversed, and only sec-
ondly, a recovery phase during which weight gain is pro-
moted [7]. Treatment of severe malnutrition in adults,
other than those with prolonged illness in high-income
countries, has been studied less often than treatment
of malnourished children. During the 1992 famine in
Somalia, Collins et al. [11] found that, similar to treatment
of children, starting adults with a low protein and lower
calorie diet intervention was associated with lower mortal-
ity than when using a high protein diet. A non-randomisedaddition of higher amounts of minerals to the low protein
diet had no additional benefit.
There has been little controlled research on nutritional
interventions for malnourished, HIV-infected Africans
[12]. A recent Cochrane review [13] found few placebo-
controlled trials, small sample sizes, and few benefits of
macronutrient interventions for HIV. A trial excluded
from the review because it compared two dietary supple-
ments, rather than having a placebo control, found
increased BMI in Malawian adults after 14 weeks of
supplementation with nutrient-dense food [14], but not
9 months after stopping supplementation [15] and no ef-
fect on the high mortality of the patients [14]. A study
conducted since the review found that lipid-based nutri-
tional supplements (LNS) given at the start of ART, com-
pared with LNS given 3 months later, increased early gains
in BMI, lean mass, and grip strength [16]. In earlier work,
we found preliminary evidence that micronutrient supple-
mentation reduced mortality [17]; sample size was small, a
feature common to all multiple micronutrient trials for
HIV-infected adults in a systematic review [18]. Neverthe-
less, this review documents evidence that provision of
additional micronutrients may have some benefits for HIV
patients. The Nutritional Support for Adults Starting Anti-
retroviral Therapy (NUSTART) trial was designed to build
on these trials and to incorporate two key lessons learned
from treating childhood malnutrition: stabilisation of nu-
tritional metabolism before introducing high energy sup-
plementation, and avoidance of iron in the early stages.
We hypothesised that provision of vitamins and minerals
and use of a two-stage intervention with stabilisation and
recovery stages would decrease the early mortality of mal-
nourished adults starting ART.
Methods
Design
The NUSTART study was a blinded phase III individually-
randomised controlled trial comparing in a two-stage
protocol vitamin and mineral supplements in a lipid-based
nutritional supplement (LNS-VM) with control LNS
administered from recruitment at referral for ART
until 6 weeks after starting ART. The primary outcome
was mortality between recruitment and 12 weeks post-
ART initiation. Secondary outcomes presented here are
other serious adverse events (SAEs) and BMI, and CD4
count at 12 weeks. The trial was registered on the Pan-
African Clinical Trials Register as PACTR201106000300631
(May 31, 2011).
Setting
The study was conducted from August 2011 to December
2013 at two sites: the National Institute for Medical
Research, Mwanza, Tanzania, and the University Teaching
Hospital, Lusaka, Zambia. In Mwanza, patients were
Table 1 Nutritional composition of trial
supplements – amounts per daya
Nutrient First phase supplement
(from recruitment to
2 weeks of ART)
Second phase
supplement (from 2
to 6 weeks of ART)
LNS-VM
(30 g)
LNS
(30 g)
LNS-VM
(250 g)
LNS
(250 g)
Calories (kcal) 139 168 1,397 1,416
Protein (g) 2.4 2.3 55 55
Fat (g) 11.0 10.9 97.5 97.5
Potassium (mmol) 30 0.9 32 15.8
Phosphorus (mmol) 47 0.4 38 9.3
Magnesium (mmol) 16 0.3 17 5.7
Calcium (mg) 29.8 5.0 140 115
Iron (mg) 0.4 0.4 14.7 8.4
Zinc (mg) 21 0.2 21 3.8
Copper (mg) 3.6 0.06 3.6 1.2
Manganese (mg) 4.2 – 4.2 –
Iodine (μg) 420 – 420 –
Selenium (μg) 180 – 180 –
Chromium (μg) 75 – 75 –
Retinol (as palmitate) (μg) 1,800 – 1,800 –
Vitamin D (μg) 10 – 10 –
Vitamin E (mg) 45 – 45 –
Vitamin K (μg) 95 – 95 –
Vitamin C (mg) 120 – 120 –
Thiamin (mg) 2.4 – 2.4 –
Riboflavin (mg) 3.3 – 3.3 –
Niacin (mg) 39 – 39 –
Pyridoxine (mg) 3.6 – 3.6 –
Folate (μg) 600 – 600 –
Vitamin B12 (μg) 4.5 – 4.5 –
Pantothenic acid (mg) 9 – 9 –
aWhere nutrient contents are provided for both LNS and LNS-VM, these are
values from analysis by the manufacturer, accounting for inter-batch variability;
where values for only LNS-VM are given, these where not assessed in the
prepared foods but refer to amounts added, that is, they do not include those
intrinsic to the LNS.
ART, Antiretroviral therapy; LNS, Lipid-based nutritional supplement; LNS-VM,
LNS with added vitamins and minerals.
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conducted at a research clinic located at the Sekou Toure
Regional Hospital. In Lusaka, patients were recruited from
six peripheral clinics which referred to the University
Teaching Hospital. At both sites, this resulted in patients
with a wide range of socioeconomic and nutritional back-
grounds. Previous work by our group at both sites con-
firmed that micronutrient deficiencies were prevalent and
that multiple micronutrient supplementation could pro-
vide benefits [19-21]. HIV prevalence among adults in the
Mwanza region is about 6% [22] and in Lusaka about 20%
[23]. In both countries, at the time of the trial, ART
was provided free for those with either CD4 lympho-
cyte count <350 cells/μL or WHO Stage 3 or 4 disease.
About a third of patients starting ART in both countries
have a BMI <18.5 kg/m2 [3,4].
Participants
Inclusion criteria were at least 18 years old, ART-naive
(except for standard regimens to prevent maternal-to-
child HIV transmission), BMI <18.5 kg/m2, requiring
ART as determined by CD4 count <350 cells/μL or
stage 3 or 4 disease, willing to undertake intensive ART
follow-up in the study clinic, and providing written (or
thumbprint if unable to write) informed consent. In the
presence of oedema, patients with BMI <20 kg/m2 were
considered; BMI was re-measured after loss of oedema,
and the patient considered eligible if BMI was <18.5 kg/m2
and ART had not yet been initiated. Exclusion criteria were
participation in a potentially conflicting research protocol
or self-reported pregnancy.
Intervention
The LNS, made for the trial by Nutriset, Malaunay, France,
contained about 60% calories as fat and 10% calories as
protein and came in ready-to-eat packets. Within each
treatment arm, the intervention products contained the
same daily amounts of vitamins and minerals in both treat-
ment stages (Table 1). Control LNS contained vehicle and
flavourings similar to vitamin and mineral-enriched LNS
(LNS-VM); it contained micronutrients intrinsic to the
bulk ingredients but had no added vitamins or minerals. In
the first stage, from recruitment to 2 weeks after starting
ART, the products were given with minimal calories, i.e.,
30 g/day, approximately 150 kcal/day. From 2 to 6 weeks
after initiating ART patients were given 250 g/day, in two
125 g sachets, comprising approximately 1,400 kcal/day. In
pilot work at the Mwanza site, the LNS products were
found acceptable to a similar group of HIV patients [24].
Products were further evaluated by study staff at both
African sites to confirm that the intervention and control
preparations were acceptable and indistinguishable.
The evidence base for micronutrient supplements for
adults on ART is extremely limited, therefore, we basedlevels in the intervention supplement on previous work
by the collaborators [8,9,17,25,26], established supple-
ments used for severely malnourished children [7], and
recent estimates of requirements for moderately mal-
nourished children [27]. The fundamental basis for the
formulation was three times the Recommended Nutrient
Intake (RNI) for British women [28], but no iron during
the first phase and only the RNI for iron during the sec-
ond phase.
Stability, safety, and micronutrient levels of the supple-
ments were monitored regularly by the manufacturer,
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sites, and found to be adequate.
Randomisation and masking
Randomisation was conducted by the Data Safety and
Monitoring Board (DSMB) statistician using computer-
generated blocks of 16 and stratified by site. An alloca-
tion code (letters A to H) indicating the contents of the
supplement packets were known only to Nutriset and
the DSMB statistician. A randomisation code linking the
allocation code to study ID numbers was held by the
DSMB statistician and site-based study pharmacists who
did not know the package contents, had no direct con-
tact with patients, and were instructed not to disclose
packaging details to the clinical teams. Packages of LNS-
VM and LNS, in both small and large dose formats,
were delivered by the producer in lots designated by
allocation code. Packets were then labelled with the
study ID numbers by the clinic pharmacists at the time
packets were dispensed. Eligible participants were re-
cruited to sequential IDs (within sites) by clinic nurses
with no access to either code. Participants were asked,
on exit from the study, if they could guess their treat-
ment. Only 616/1,256 (49%) patients said they could
guess, and of these, 83% in both treatment groups
guessed they were on the high vitamins and minerals
supplement.
Adherence
At each visit, patients were provided with sufficient sa-
chets of LNS or LNS-VM to last until their next sched-
uled visit. Adherence to both intervention supplements
was monitored by asking participants to return empty
packages at their next visit. Overall adherence was calcu-
lated as total empty packages returned divided by total
packages expected to be consumed. When patients died
or stopped attending study visits, data on returned pack-
ages was missing. In these cases, it was assumed that all
of the packages given at their last study visit were con-
sumed. A sensitivity analysis was carried out assuming
that none of these packages were consumed.
Sample size justification
The primary outcome was mortality within the study
period which was estimated to include about 4 weeks
pre-ART and 12 weeks of ART. Calculations of sample
size were based on two studies from urban Africa: one
study in Cape Town [29], which separated the high mor-
tality pre-ART phase from mortality after starting ART,
and one from Lusaka, with a patient population similar
to that expected in the proposed study [3]. We assumed
a mortality rate in the control group of 25/100 person-
years, based on post-ART mortality of Zambian patients
starting ART with a BMI of 17 to 18.49 kg/m2. Wecalculated that 1,150 patients per treatment arm, with
5% loss to follow-up, would provide >90% power to de-
tect a 50% reduction in mortality, similar to the mortal-
ity difference between Zambian patients with plasma
phosphate above and below the median [8], and less
than the mortality reduction achieved through multiple
micronutrient supplementation of Thai patients with
low CD4 counts before ART was locally available [25]. It
became apparent, by June 2013, that the trial would be
unable to recruit all planned participants within the
funding available; however, mortality was higher than ex-
pected (see Results). The steering group asked the DSMB
to consider futility, in addition to a planned interim efficacy
analysis, at this point. The DSMB recommended that re-
cruitment could cease. Therefore, recruitment stopped in
July 2013 with a total of 1,815 participants which was esti-
mated, considering actual mortality, as sufficient to detect,
with 90% power, a reduction in mortality of 30%.
Participant recruitment and follow-up
Adults attending free HIV testing services at both sites,
eligible for ART and fulfilling the study inclusion criteria,
were deemed eligible for the trial. Before initiating ART
as part of routine care, patients were screened, com-
menced on treatment for opportunistic infections, and
counselled regarding lifelong treatment adherence. During
this pre-ART period, the first stage study interventions
were introduced. Medical care was provided primarily
by local health services, although study staff treated
and referred as necessary during the patients’ study visits.
National treatment guidelines for ART regimen differed
in the two countries: most Zambians were prescribed
Efavirenz/Tenofovir/Emtricitabine, whereas a wider range
of regimens were prescribed to Tanzanians.
Patients were seen weekly from recruitment until the
ART initiation visit, then at 2, 4, 6, 8, and 12 weeks after
starting ART. Patients who were ill could come for un-
scheduled visits at any time. Patients were actively
followed-up if they missed scheduled visits; patients and
relatives were phoned, their ART clinics were contacted,
and, in Mwanza, they were visited at home. We were
thus able to ascertain the primary outcome, mortality,
on a greater number of patients than those attending the
week 12 visit for secondary outcomes.
Outcomes
The primary outcome was death between recruitment
and 12 weeks after starting ART, based either on reports
from medical facilities or from relatives. In order to cap-
ture serious illnesses which did not result in death, a
second outcome was hospitalisation, defined as at least
overnight admission to a hospital, including inpatient fa-
cilities attached to clinics. Diagnoses and duration of
hospitalisation were recorded.
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in death, hospitalisation, or permanent disability, or were
life-threatening, as well as a drug overdose or cancer.
Low serum phosphate and low or high serum potassium
levels of US National Institutes of Health Division of
AIDS (DAIDS [30]) grade 3 and 4 were considered se-
vere laboratory adverse events. DAIDS does not set high
ranges for phosphate but, because we were also inter-
ested in potential excesses from supplementation, we
classified any above-normal limits as adverse events [31].
Analysis of magnesium levels was also planned, however
for technical reasons, results were only available for few
patients and did not show much of clinical interest or
association with other data, and were therefore omitted.
Alanine aminotransferase (ALT) at baseline and 12 weeks
after starting ART was investigated in a non-random
subset of patients recruited later in the trial following a
report of raised ALT associated with high dose micronu-
trients in a trial of HIV patients in Tanzania [32].
Weight was measured at all visits and height at re-
cruitment if the patient was able to stand; data from the
screening visit were used if the patient was unable to
stand. Measurements were taken in triplicate and the
median used in analyses. Data for the final visit were
used for all who attended up to 14 days before or after
the official follow-up end date of 12 weeks since starting
ART.
Laboratory analyses
Venous blood samples were taken at all scheduled visits.
CD4 count (baseline and week 12 only) was measured
by local central clinical services. In Lusaka, serum phos-
phate was measured spectrochemically on a Pointe 180
analyser (Bactlabs East Africa, Nairobi, Kenya). Sample
results were accepted only from runs for which the ex-
ternal quality control (QC) sample from the same sup-
plier was within expected range. Inter-assay coefficient
of variation (CV) for this external QC was 7%. In Mwanza,
serum phosphate was measured in an external laboratory
(Bugando Medical Centre) using a Roche COBAS Integra
400 analyser. Serum potassium was measured by optical
emission using Perkin Elmer Optima 7000 ICP (Perkin
Elmer, South Africa). An external QC (Seronorm, Alere,
Cheshire, UK) was run each day and values were within ex-
pected limits at both sites. CVs for potassium were 5% in
Mwanza and 6% in Lusaka. Both sites experienced periods
when the Optima machines were out of order so
samples were sent to Bugando laboratory in Mwanza and
the Centre for Infectious Diseases Research in Zambia
(CIDRZ) laboratory in Lusaka. The Pointe 180 was used at
both sites to measure ALT. Values for the external QCs
(Bactlabs East Africa, Nairobi, Kenya) were very slightly
under the expected ranges at both sites; inter-assay CVs
were 14% in Lusaka and 10% in Mwanza.Data management and statistics
Data were double entered into OpenClinica data man-
agement system in Lusaka and into CSPro 4.1 and
stored in MySQL databases in Mwanza. Analyses were
conducted in STATA version 13.1. Primary statistical
analysis was by intention-to-treat, and per protocol ana-
lyses were also conducted to account for adherence to
treatments. The primary analysis compared mortality rates
between treatment groups by Cox regression. Robust
standard errors Cox regression was performed to deter-
mine effects of the intervention on hospitalisation rate
and occurrence of clinical and laboratory SAEs accounting
for repeat events. Proportional hazards assumptions were
examined using cumulative hazard plots and Schoenfeld
residuals [33]. Mean BMI and CD4 at 12 weeks were com-
pared between groups using t-tests and linear regression,
adjusting for baseline values. Pre-planned analyses deter-
mined whether treatment effects were modified by coun-
try, sex, initial BMI (< or ≥17 kg/m2), initial CD4 count
(< or ≥100 cells/μL), or TB treatment pre-ART using
Cox regression with an interaction term between treat-
ment arm and potential effect modifier. Principal com-
ponents analysis, used to describe the socio-economic
status of the population [34], was conducted separately
for each country since there were notable differences
between sites; variables offered into the principal compo-
nents analysis were housing characteristics, sanitation,
water source, and ownership of electrical goods, animals,
and modes of transport.
Ethics
Ethical approval was obtained from the research ethics
committee of the London School of Hygiene and Tropical
Medicine, the University of Zambia Biomedical Research
Ethics Committee, and the Medical Research Coordinating
Committee of National Institute for Medical Research,
Tanzania. All participants provided written or thumbprint
informed consent. Medical care of patients was according
to national guidelines and provided through the local
health services. Patients with low levels of serum electro-
lytes according to DAIDS criteria were provided appropri-
ate electrolyte therapy.
Results
Participants and follow-up
Figure 1 shows the flow of participants through the
study and Table 2 describes the population at recruit-
ment. Characteristics of the population were similar
at baseline between treatment arms. Compared with
Zambian participants, Tanzanian participants had lower
CD4 counts and blood haemoglobin, had less education,
and were more likely to be self-employed but less likely to
be salaried or unemployed (data not shown). Oedema was
uncommon at baseline and all patients with oedema had
Figure 1 Flow of participants through the study. Screening in Mwanza was of all HIV-infected patients referred for CD4 testing, whereas in
Lusaka only patients who also had body mass index <18.5 kg/m2 were formally screened; this resulted in a greater proportion of ineligible
patients in Mwanza. LNS, Lipid-based nutritional supplement without added vitamins and minerals; LNS-VM, Lipid nutritional supplement with
added vitamins and minerals. 1 Not meeting inclusion criteria (n = 2,608): 5 < 18 yr, 17 non-ART naive, 303 BMI >18.5 kg/m2, 16 unwilling for
intensive follow-up, 10 pregnant, 4 enrolled in other study, 21 refused CD4 count, 2,222 not eligible for ART, 10 unwilling to start ART.
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Table 2 Baseline characteristics of the study population
Variable Level LNS-VM LNS
n (%) 914 (50.4) 901 (49.6)
Age (years), mean (SD) 35.9 (9.4) 35.7 (9.4)
Female, n (%) 443 (49) 457 (51)
Marital status, n (%) Married/Cohabiting 420 (46) 438 (49)
Widowed 96 (11) 107 (12)
Divorced/Separated 266 (29) 244 (27)
Single 132 (14) 111 (12)
Missing 0 (0) 1 (0.1)
Occupation, n (%) Salaried 134 (15) 137 (15)
Self-employed 485 (53) 460 (51)
Housewife 86 (9) 97 (11)
Student 9 (1) 9 (1)
Unemployed 200 (22) 197 (22)
Missing 0 (0) 1 (0.1)
Education, n (%) None 170 (19) 173 (19)
Primary 528 (58) 517 (57)
Secondary 192 (21) 185 (21)
Tertiary 24 (3) 25 (3)
Missing 0 (0) 1 (0.1)
Socioeconomic quintilesb,
n (%)
Lowest 166 (18) 198 (22)
Low 185 (20) 189 (21)
Middle 200 (22) 162 (18)
High 173 (19) 182 (20)
Highest 190 (21) 170 (19)
BMI (kg/m2), mean (sd) 16.4 (1.4) 16.4 (1.4)
BMI <17 kg/m2, n (%) 542 (59) 532 (59)
CD4 count (cells/μL),
mean (SD)
134 (97) 139 (103)
CD4 count group, n (%)
at each
<50 227 (25) 216 (24)
range of cells/μL 50–99 171 (19) 176 (20)
100–199 279 (31) 252 (28)
≥200 237 (26) 257 (29)
Haemoglobin (g/L),
mean (SD)
95 (23) 97 (24)
Haemoglobin groupa, n (%) Severe anaemia 207 (23) 191 (21)
Moderate anaemia 422 (46) 388 (43)
Mild anaemia 128 (14) 157 (17)
Normal 82 (9) 95 (11)
Missing 75 (8) 70 (8)
Phosphate <0.87 mmol/L,
n (%)
<0.87 113 (12) 83 (9)
Missing 26 (3) 25 (3)
Table 2 Baseline characteristics of the study population
(Continued)
Potassium <3.5 mmol/L,
n (%)
<3.5 133 (15) 141 (16)
Missing 53 (6) 52 (6)
TB treatment pre-ART, n (%) 252 (28) 199 (22)
Oedema at baseline, n (%) 31 (3) 35 (4)
Initial ART regimen, n (%) AZT/3TC/EFV 68 (10) 67 (9)
AZT/3TC/NVP 111 (16) 125 (17)
TDF/FTC/EFV 418 (58) 398 (55)
TDF/FTC/NVP 31 (4) 33 (5)
Other 30 (4) 24 (3)
Missing 59 (8) 71 (10)
BMI, Body mass index; CI, Confidence interval; LNS, Lipid-based nutritional
supplement without added vitamins and minerals; LNS-VM, Lipid nutritional
supplement with added vitamins and minerals; AZT, Zidovudine; 3TC, Lamivudine;
NVP, Nevirapine; TDF, Tenofovir; EFV, Efavirenz; FTC, Emtricitabine.
aHaemoglobin categories were selected based on usual nutritional cut-offs,
not as defined for specific adverse events; adequate haemoglobin was defined
as 130 g/L for men and 120 g/L for women; mild anaemia was 110 g/L to the
adequate cut-off; moderate anaemia was 80–109 g/L; severe anaemia
was <80 g/L.
bSocioeconomic quintiles analysed for each site separately by principal
component analysis.
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ticipants was 137 cells/μL (SD 100). Low plasma phos-
phate was found in 196 patients (11%), low potassium in
274 (16%), and anaemia was common at recruitment. A
quarter of participants were started on TB treatment be-
fore initiating ART.
Total follow-up time was 439 person-years. Partici-
pants attended 6,657 clinic visits in the LNS-VM arm
and 6,282 clinic visits in the LNS arm over the course of
the study. The median time between study enrolment
and ART initiation was 21 days (interquartile range
(IQR), 15–30) in both the LNS-VM and the LNS arm.
Overall median follow-up periods were: all participants,
14.3 weeks (IQR, 10.4–15.7); all those who completed
follow-up, 15 weeks (IQR, 14.1–16.3); all those who
died, 5.7 weeks (IQR, 3.1–9.1); and all those lost to
follow-up, 3.1 weeks (IQR, 1–8.1). There were 173 (9.5%)
participants who were lost to study follow-up or withdrew
consent and were censored at last contact with study team;
median duration of follow-up did not differ between treat-
ment arms.
Mortality
There were 184 deaths in the LNS-VM arm, 82.6/100
person-years (95% CI, 71.4–95.4), and 181 deaths in
the LNS arm, 83.7/100 person-years (95% CI, 72.3–96.8;
Figure 2 and Table 3). The mortality rate ratio (RR) was
0.99 (95% CI, 0.80–1.21; P = 0.89). In planned stratified
regression analyses, participant country, sex, initial BMI,
initial CD4 count, initial low phosphate or potassium, or
Figure 2 Effect of treatment allocation on mortality. LNS,
Lipid-based nutritional supplement without added vitamins and
minerals; LNS-VM, Lipid nutritional supplement with added vitamins
and minerals. The X axis presents total time in the study in months,
irrespective of individual times after recruitment when a patient
started antiretroviral therapy (ART); median time between recruitment
and start of ART was 21 days (0.75 months).
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did not modify the effect of the intervention on mortal-
ity. There was also no effect of the intervention on mor-
tality if the pre- and post-starting ART periods were
examined separately.
Only 710 (39%) of patients consumed at least 75% of
the expected number of sachets of supplement for their
time in the study. When the mortality analysis was re-
stricted to these patients with higher adherence to the
intervention, mortality rates were lower than in the full
cohort but there remained no evidence of a difference in
RR (RR, 0.84; 95% CI, 0.59–1.21). In the sensitivity ana-
lysis, assuming patients did not consume supplements
from their last visit, the RR was 1.19 (95% CI, 0.61–2.35).
Adherence to ART medication was very good: adherence
of at least 95% was observed in 622 (96%) of those receiv-
ing LNS-VM and in 607 (95%) of those receiving LNS
(RR, 1.1; 95% CI, 0.64–1.88, P = 0.73).
Secondary outcomes
There was no evidence of differences between treatment
arms in clinical SAEs, although there was a trend to-
wards lower rates in the LNS-VM group (Table 4). There
was evidence of a decreased incidence of severely low
phosphate in the LNS-VM group. Examining all levels
above the normal range, there was strong evidence of
increased incidence of both high phosphate and high po-
tassium in the LNS-VM group (Figure 3).
After controlling for baseline CD4 count, there was
evidence that mean CD4 count at 12 weeks post-ART
was higher in the LNS-VM compared with the LNS
group (adjusted difference, 25 cells/μL; 95% CI, 4–46;P = 0.02; Table 5). Controlling for baseline BMI, mean BMI
at 12 weeks was not significantly greater in the LNS-VM
compared with the LNS group. There was no evidence that
mildly elevated ALT (>40 U/L) at 12 weeks was more
prevalent in the LNS-VM group (12/74 (16%) versus 6/62
(10%) in the LNS group; P = 0.26).
Discussion
High early mortality in ART programmes in sub-Saharan
Africa is an ongoing concern, and early work suggested that
nutritional interventions may hold out some hope of bene-
fit. In this randomised controlled trial of a fairly high dose,
usually three times the RNI, of vitamins and minerals,
added to a two-stage lipid-based nutritional supplement, we
found no reduction in mortality in the intervention group.
A trial comparing very high doses of vitamins with one RNI
in a similar population also found no benefits for mortality
[32]. The NUSTART nutritional intervention did, however,
have a modest benefit for CD4 count.
The trial benefited from its large sample size, excellent
follow-up for the primary outcome, and regular collec-
tion of detailed clinical and laboratory data. A limitation
was the need to stop recruitment before the originally
planned number of patients; although this did not jeop-
ardise the primary outcome because of the unexpectedly
high mortality rate, it may nevertheless have limited
power to detect changes in some secondary outcomes. A
second limitation was the low proportion of people with
adequate compliance to the intervention. Because our
pilot data showed the supplements were well liked [24],
we think low compliance is more likely due to the diffi-
culties of following up very ill patients for long-term
care in urban and periurban African environments –
patients needed to attend study visits both to collect
supplements and to return empty sachets for compliance
estimation – as well as the greater difficulties for patients
with regards to compliance with high calorie food inter-
ventions than with pills. Compliance could have been over-
estimated if patients shared their sachets with household
members. However, we think this unlikely as the import-
ance of taking the supplement was emphasised at each
study visit, patients were questioned at each visit, and shar-
ing was reported in less than 1% of cases. Furthermore,
compliance could have been underestimated as we relied
on patients returning their empty sachets. Finally, although
we based the amount of LNS supplied on amounts used in
similar studies [14,16], the full amount may not be required
to improve CD4 count and some anthropometric measures
(Rehman et al., submitted), since benefits were seen despite
poor adherence. Future studies of LNS provision could
perhaps save costs by providing smaller amounts.
The NUSTART intervention was based on similar nutri-
tional supplementation strategies used for severely mal-
nourished young children and includes several underlying
Table 3 Effects of intervention on overall and subgroup mortality
n Deaths Mortality rate per 100 person-years
(95% CI)
Rate ratiob (95% CI) P value P value for
modification
Total intention to treat analysis LNS-VM 914 184 82.6 (71.4–95.4) 0.99 (0.80–1.21) 0.89
LNS 901 181 83.7 (72.3–96.8)
Per protocol analysisa LNS-VM 356 56 64.2 (49.4–83.4) 0.84 (0.59–1.21) 0.35
LNS 354 64 76.9 (60.2–98.2)
Pre-ART period LNS-VM 896 79 113.6 (91.2–141.7) 1.0 (0.75–1.43) 0.81
LNS 888 72 108.0 (85.7–136.0) 0.53
Post-ART period LNS-VM 740 97 64.1 (52.5–78.2) 0.91 (0.69–1.19) 0.49
LNS 741 105 70.8 (58.5–85.7)
Men LNS-VM 471 105 94.9 (78.4 to114.9) 0.97 (0.74–1.27) 0.82
LNS 444 104 97.5 (80.4–118.2) 0.87
Women LNS-VM 443 79 70.4 (56.4–87.7) 1.00 (0.73–1.37) 0.98
LNS 457 77 70.2 (56.2–87.8)
Zambia LNS-VM 559 85 60.8 (49.1–75.2) 0.96 (0.71–1.30) 0.80
LNS 552 85 63.2 (51.1–78.2) 0.81
Tanzania LNS-VM 355 99 119.3 (97.9–145.2) 1.01 (0.76–1.34) 0.93
LNS 349 96 117.3 (96.0–143.3)
BMI <17.0 kg/m2 LNS-VM 542 135 106.8 (90.2–126.4) 1.05 (0.83–1.34) 0.68
LNS 532 124 101.4 (85.0–120.9) 0.32
BMI ≥17.0 kg/m2 LNS-VM 372 49 50.8 (38.4–67.2) 0.84 (0.57–1.22) 0.36
LNS 369 57 60.6 (46.8–78.6)
CD4 < 100 /μL LNS-VM 398 107 117.3 (97.0–141.8) 0.89 (0.69–1.16) 0.39
LNS 392 117 131.7 (109.9–157.9) 0.22
CD4≥ 100 /μL LNS-VM 516 77 58.5 (46.8–73.1) 1.16 (0.83–1.62) 0.38
LNS 509 64 50.2 (39.3–64.1)
On TB treatment before ART LNS-VM 252 38 57.9 (42.2–79.6) 1.30 (0.78–2.16) 0.32
LNS 199 24 44.3 (29.7–66.1) 0.29
Not on TB treatment before ART LNS-VM 662 146 92.8 (78.9–109.2) 0.96 (0.76–1.20) 0.71
LNS 702 157 96.8 (82.8–113.2)
Phosphate <0.87 mmol/L LNS-VM 113 25 93.5 (63.1–138.3) 0.99 (0.54–1.79) 0.96
LNS 83 19 93.5 (59.6–146.5) 0.998
Phosphate ≥0.87 mmol/L LNS-VM 775 152 79.8 (68.0–93.5) 0.99 (0.79–1.23) 0.90
LNS 793 154 80.9 (69.1–94.7)
Potassium <3.5 mmol/L LNS-VM 133 34 113.8 (81.3–159.3) 0.87 (0.55–1.37) 0.54
LNS 141 40 130.3 (95.6–177.7) 0.69
Potassium ≥3.5 mmol/L LNS-VM 728 137 76.0 (64.3–89.8) 0.96 (0.76–1.22) 0.76
LNS 708 136 79.3 (67.1–93.8)
BMI, Body mass index; CI, Confidence interval; LNS, Lipid-based nutritional supplement without added vitamins and minerals; LNS-VM, Lipid nutritional supplement
with added vitamins and minerals; TB, Tuberculosis.
aIncluded only participants who consumed at least 75% of their expected supplement sachets; bRate ratio from Cox regression analysis.
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tissue deposition; micronutrient metabolism, especially
for iron and anti-oxidants; and the need to stabilise
metabolism before giving high calorie supplements to
promote nutritional recovery. Our results suggest thatthese underlying concepts may have had a different im-
portance for the health of our patient population, with
consequent mixed outcomes.
First, regarding electrolyte metabolism and requirements,
our results suggest that, although low levels of phosphate
Table 4 Effect of intervention on adverse events (AEs)
Events Event rate per 100 person-years (95% CI) Rate ratio (95% CI)a P value
Clinical AEs
Hospitalisation LNS-VM 170 76.3 (65.6–88.6) 0.87 (0.71–1.07) 0.19
LNS 190 87.8 (76.2–101.2)
All serious clinical adverse eventsb LNS-VM 250 112.2 (99.1–127.0) 0.89 (0.75–1.06) 0.20
LNS 272 125.7 (111.6–141.6)
Severe laboratory AEsc
Potassium >6.5 mmol/L LNS-VM 29 13.0 (9.0–18.7) 1.66 (0.91–3.02) 0.097
LNS 17 7.9 (4.9–12.6)
Potassium <2.5 mmol/L LNS-VM 28 12.6 (8.7–18.2) 0.82 (0.50–1.36) 0.44
LNS 33 15.3 (10.8–21.5)
Phosphate <0.65 mmol/L LNS-VM 86 38.7 (31.2–47.7) 0.73 (0.55–0.97) 0.03
LNS 114 52.7 (43.9–63.3)
Abnormally high electrolyte levelsd
Potassium >5.5 mmol/L LNS-VM 117 52.5 (43.8–62.9) 1.60 (1.19–2.15) 0.002
LNS 71 32.8 (26.0–41.4)
Phosphate >1.45 mmol/L LNS-VM 650 219.6 (270.1–314.9) 1.23 (1.10–1.37) <0.001
LNS 513 237.1 (217.5–258.6)
CI, Confidence interval; LNS, Lipid-based nutritional supplement without added vitamins and minerals; LNS-VM, Lipid nutritional supplement with added vitamins
and minerals.
aAccounting for repeat events by patient; bDeath, hospitalisation, life-threatening events, permanently disabling, congenital abnormality, cancer, drug overdose;
cPlasma potassium or phosphate levels meeting DAIDS criteria severity 3 or 4; dDAIDS criteria severity at least 1 for potassium and above normal [31] for
phosphate for which DAIDS has no high level cut-offs.
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patients previously reported [8], the hypothesis that
providing supplemental oral electrolytes would decrease
mortality risk was not proved correct. It is possible that
any benefits of supplementation were masked by the in-
tensive medical care provided by the trial clinical teams.
We measured patient blood electrolytes at all visits in
order to inform our understanding of the effect of the
intervention and for patient safety. Patients with low
electrolytes were found slightly more often in the LNS
than the LNS-VM group. For ethical reasons, these pa-
tients were treated (whenever they could be traced
quickly, which was not always possible in the context
of sprawling African urban and periurban areas) usually
with oral supplements. We do not know whether this treat-
ment prevented some severe derangements and thus hos-
pitalisations and deaths.
We did not expect to find many cases of high electro-
lytes with the supplement as designed and were surprised
by the increased rate of both phosphate and potassium
events. The amount of potassium (~30 mmol/day) in the
LNS-VM was actually low in terms of potassium balance
in a healthy adult (RNI 50 to 90 mmol/day [28]), but was
the maximum the manufacturer was able to add without
compromising taste and acceptability of the supplement.
However, in some participants, the amount appeared to bemore than their metabolism could handle. The daily dose
of phosphate was almost triple the RNI since we have pre-
viously shown that low phosphate is associated with a
poor outcome in this patient group [8]. Not all of the
adverse electrolyte events recorded would be clinically sig-
nificant; for example, short term rises in plasma phosphate
do not predictably lead to any clinical consequences. High
potassium is more worrying and is the only one of the
electrolytes we measured which has DAIDS criteria listed
for high values. The evidence for a difference in severely
high potassium is weak, but this could be a result of the
small numbers involved. There were 175 people who de-
veloped a potassium value above the normal range of
whom 24 (14%) died. While this is a lower risk of death
than for the whole study cohort, it is not a reason for com-
placency as the longer a patient stayed alive in the study,
the more opportunity they had to be diagnosed with an
abnormal electrolyte value. Further, among these 175 pa-
tients, the mortality rate was two and half times higher in
those taking LNS-VM (hazards ratio, 2.54; 95% CI, 0.95–
6.82; P = 0.06) suggesting their electrolyte abnormality was
more severe. This is an important finding and we would
recommend that malnourished HIV-positive people are
not given blanket treatment with potassium supplements.
The addition of phosphate to nutrition supplements should
be kept at low levels.
Figure 3 Effect of treatment allocation on time to first event
of plasma phosphate or potassium higher than the normal
range. The cut-offs for values greater than the normal range were
1.45 mmol/L for phosphate and 5.5 mmol/L for potassium [31].
LNS, Lipid-based nutritional supplement without added vitamins
and minerals; LNS-VM, Lipid nutritional supplement with added
vitamins and minerals.
Table 5 Effects of intervention on body mass index (BMI), blo
n Mean at end of study (SD) Differen
(95% C
BMI (kg/m2) LNS-VM 421 18.5 (1.8) 0.15 (−0
LNS 392 18.4 (1.9)
CD4 count/μL LNS-VM 404 297 (188) 17 (−8–
LNS 355 280 (154)
ALT (U/L) LNS-VM 74 26.4 (1.4) −0.3 (−4
LNS 62 26.6 (1.6)
CI, Confidence interval; LNS, Lipid-based nutritional supplement without added vita
and minerals.
aAdjusted for baseline values; sample size for adjusted analysis for ALT was reduced
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and trial design – that high levels of electrolytes and
micronutrients would promote recovery – is supported
by the modest increase in CD4 count in the LNS-VM
group. A recent review found few nutritional supple-
mentation trials with CD4 count as an outcome and no
evidence of benefits of food or nutrition education inter-
ventions [13]. A review focussing on micronutrient sup-
plements in HIV found some evidence of benefits of
multiple micronutrient supplements for CD4 count [18];
however, evidence was limited and much of the research
focussed on pregnant women or was conducted before
ART was widely available. Thus, vitamin and mineral
supplementation to improve immunological recovery in
seriously ill HIV patients clearly merits further investiga-
tion, especially since early robust recovery of CD4 count
may be particularly important for survival of patients
with a low BMI [35]. Other aspects of nutritional recov-
ery are among the NUSTART trial secondary outcomes
to be reported later. It should be noted that, because pa-
tients were severely malnourished, the control group
received LNS, which contained innate vitamins and min-
erals as well as calories and may have provided health
benefits; this is supported by a trial of less malnourished
patients in Ethiopia in which inclusion of a delayed sup-
plementation control group demonstrated nutritional
benefits of providing LNS at the start of ART [16].
The mortality rate seen in our trial was higher than re-
ported in most studies for patients starting ART, includ-
ing in the two studies used to estimate the required
sample size [3,29]. We believe this was due to a combin-
ation of the lower BMI of patients in NUSTART than in
the other cohorts and on our inclusion of patients dur-
ing the high-risk period immediately pre-ART [29]. We
note that NUSTART post-ART initiation mortality rates
were similar to rates for the same BMI categories in an-
other study from Tanzania [4], but we are unaware of other
studies that have reported outcomes for this combinationod CD4 count, and alanine aminotransferase (ALT)
ce in means
I)
P value Adjusted difference in meansa
(95% CI)
P value
.10–0.41) 0.23 0.15 (−0.08–0.37) 0.20
42) 0.18 25 (4–46) 0.02
.4–3.9) 0.90 −0.98 (−5.2–3.3) 0.65
mins and minerals; LNS-VM, Lipid nutritional supplement with added vitamins
because of missing baseline values: 71 in LNS-VM, 61 in LNS.
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We are in the process of analysing the mortality risk-
factors in more detail. However, the high mortality seen
emphasises the importance of prompt diagnosis and treat-
ment for malnourished HIV-infected people.
We measured serum ALT in only a subset of patients
after a trial with a high micronutrient supplement for a
similar group of HIV-infected patients found increased
ALT in the intervention group [32]. However, we found
no differences in ALT between treatment arms, suggest-
ing that this may not be a serious issue.
Conclusions
In summary, the intervention protocol did not decrease
mortality or SAEs, although it did benefit a secondary
outcome, CD4 count. It is possible that the electrolyte
component of the supplement had no benefits due to the
study design, where electrolytes were measured regularly
and electrolyte therapy provided as needed, and to the ex-
cess of high electrolytes. Nevertheless, the benefit for CD4
count in this large trial, added to previous information
from smaller trials of micronutrient supplements for HIV
patients, suggests that micronutrient supplementation
should be pursued. Further research into metabolic causes
of the early mortality among malnourished Africans start-
ing ART is warranted. It will also be important to address
how to improve compliance with similar nutritional inter-
ventions. Finally, it will be informative to follow-up the
NUSTART patients to determine whether modest early
changes in CD4 count or nutritional status have long-term
effects.
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